Abstract:Objectives: With the advent of poly (adenosine diphosphate [ADP]- ribose) polymerase inhibitors (PARPi), first-line (1L) maintenance therapy in patients with ovarian cancer (OC) has evolved in recent years. This study described the use of 1L maintenance and assessed predictors of 1L PARPi maintenance therapy use among PARPi- eligible patients with OC in a real-world setting. Methods: This retrospective cohort study included patients with newly diagnosed stage III/IV epithelial OC who received the last dose of 1L platinum-based chemotherapy (PBC) between January 1, 2017, and February 28, 2021, from the nationwide Flatiron Health electronic health record-derived database. During the study period, the de-identified data originated from approximately 280 US cancer clinics. The end of the last cycle of 1L PBC was defined as the index date. Patients who started a second-line treatment within two months of the index date were excluded. Multivariable logistic regression was used to identify predictors of 1L PARPi monotherapy use versus active surveillance (AS). Variables included in the model were selected using the stepwise approach. Results: A total of 1010 patients were included in the study; 37.9% and 62.1% of patients received maintenance therapy and AS, respectively. A total of 162 (16.0%) patients received PARPi monotherapies (niraparib 6.3%, olaparib 8.7%, and rucaparib 1.0%), 122 (12.1%) received bevacizumab monotherapy, 33 (3.3%) received bevacizumab + PARPi combination therapies and 66 (6.5%) received other therapies. The median age was 68.0 years (Q1:58.0; Q3:75.0) for AS and 65.0 years (56.0; 71.8) for PARPi monotherapies. Other patient characteristics are shown in Table 1. Patients with BRCA mutation were significantly more likely to receive PARPi monotherapies (odds ratio [OR]: 7.49; 95% CI: 4.21-13.31) than patients with BRCA wild-type. Patients treated in 2019 (OR: 7.57; 95% CI: 3.86-14.86) and 2020 (OR: 14.99; 95% CI: 7.61-29.53) were significantly more likely to receive PARPi monotherapies than patients treated in 2017. Race, region of residence, practice type, FIGO stage at initial diagnosis, Eastern Cooperative Oncology Group (ECOG) score, residual disease status, and other disease characteristics were not selected into the model. Conclusions: Over the last four years, the use of 1L PARPi maintenance among ovarian cancer patients has increased significantly, mostly driven by biomarker status. However, stage and extent of residual disease after surgery were not associated with PARPi maintenance use. Objectives: With the advent of poly (adenosine diphosphate [ADP]- ribose) polymerase inhibitors (PARPi), first-line (1L) maintenance therapy in patients with ovarian cancer (OC) has evolved in recent years. This study described the use of 1L maintenance and assessed predictors of 1L PARPi maintenance therapy use among PARPi- eligible patients with OC in a real-world setting. Methods: This retrospective cohort study included patients with newly diagnosed stage III/IV epithelial OC who received the last dose of 1L platinum-based chemotherapy (PBC) between January 1, 2017, and February 28, 2021, from the nationwide Flatiron Health electronic health record-derived database. During the study period, the de-identified data originated from approximately 280 US cancer clinics. The end of the last cycle of 1L PBC was defined as the index date. Patients who started a second-line treatment within two months of the index date were excluded. Multivariable logistic regression was used to identify predictors of 1L PARPi monotherapy use versus active surveillance (AS). Variables included in the model were selected using the stepwise approach. Results: A total of 1010 patients were included in the study; 37.9% and 62.1% of patients received maintenance therapy and AS, respectively. A total of 162 (16.0%) patients received PARPi monotherapies (niraparib 6.3%, olaparib 8.7%, and rucaparib 1.0%), 122 (12.1%) received bevacizumab monotherapy, 33 (3.3%) received bevacizumab + PARPi combination therapies and 66 (6.5%) received other therapies. The median age was 68.0 years (Q1:58.0; Q3:75.0) for AS and 65.0 years (56.0; 71.8) for PARPi monotherapies. Other patient characteristics are shown in Table 1. Patients with BRCA mutation were significantly more likely to receive PARPi monotherapies (odds ratio [OR]: 7.49; 95% CI: 4.21-13.31) than patients with BRCA wild-type. Patients treated in 2019 (OR: 7.57; 95% CI: 3.86-14.86) and 2020 (OR: 14.99; 95% CI: 7.61-29.53) were significantly more likely to receive PARPi monotherapies than patients treated in 2017. Race, region of residence, practice type, FIGO stage at initial diagnosis, Eastern Cooperative Oncology Group (ECOG) score, residual disease status, and other disease characteristics were not selected into the model. Conclusions: Over the last four years, the use of 1L PARPi maintenance among ovarian cancer patients has increased significantly, mostly driven by biomarker status. However, stage and extent of residual disease after surgery were not associated with PARPi maintenance use.

To Bev or Not to Bev during Ovarian Cancer Maintenance Therapy?

Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics

Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment

Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer

First-line maintenance use among patients with advanced ovarian cancer in a community oncology setting: A retrospective observational study in the United States (US).

A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program.

Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice

Pharmaceutical Management of Ovarian Cancer: Current Status

Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study

Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature

EP262/#507 Adoption of New First-Line Maintenance Strategies among Patients with Primary Advanced Ovarian Cancer after Food and Drug Administration Approval

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis

Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy

Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer

Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021

Poly (adenosine Diphosphate [Adp]-Ribose) Polymerase Inhibitor First-Line Maintenance among Patients with Newly Diagnosed Advanced Ovarian Cancer in a Real-World Database (351)

OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039)

PARP Inhibitor Rechallenge Could Be an Effective Strategy in Platinum-Sensitive Ovarian Cancer: A Retrospective Study